Drug Profile
Research programme: Rho-associated kinase inhibitors - Kadmon Pharmaceuticals
Alternative Names: KD 045Latest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Surface Logix
- Developer Kadmon Pharmaceuticals; Surface Logix
- Class Antineoplastics; Antirheumatics; Immunotherapies; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Fibrosis; Glaucoma; Graft-versus-host disease; Lupus vulgaris; Metabolic disorders
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 27 Dec 2022 Discontinued - Preclinical for Cancer in USA (PO)
- 27 Dec 2022 Discontinued - Preclinical for Fibrosis in USA (PO)